PSA、CYFRA21-1、CA153、CEA的联合检测在乳腺癌中的临床价值

The Value of Combined Measurement of PSA,CYFRA21-1,CA153 and CEA Used in Breast Cancinoma

目的:探讨PSA、CYFRA21-1、CA153、CEA的联合检测在乳腺癌中的临床价值。方法:采用化学发光法测定乳腺癌患者、乳腺良性疾病和正常对照组的PSA、CYFRA21-1、CA153、CEA水平,评价其在乳腺癌早期诊断和病情监测、预后评估中的价值。结果:乳腺癌组的PSA、CYFRA21-1、CA153、CEA水平明显高于乳腺良性疾病组和正常对照组的水平。PSA、CYFRA21-1、CA153、CEA的联合检测能有效提高敏感性及准确性。结论:PSA、CYFRA21-1、CA153、CEA的联合检测可有效提高乳腺癌早期诊断率,在乳腺癌诊断病情监测和预后评估中为临床提供更为准确的辅助诊断依据。

Objective：To investigate the value of combined measurement of PSA,CYFRA21-1,CA153 and CEA used in breast cancinoma.Methods：PSA,CYFRA21-1,CA153,CEA were measured in breast cacinoma and benign lesions with chemiluminescence method,and compared with the normal group.It was estimated that the value of using in breast cancinoma early diagnosis,condition monitoring and prognosis evaluation.Results：PSA,CYFRA21-1,CA153,CEA in group of breast cancinoma is significantly higher than that of benign lesion and normal group.Combined measurement of PSA,CYFRA21-1,CA153 and CEA is useful in improvement the sensitivity and accuracy.Conclusion：Combined measurement of PSA,CYFRA21-1,CA153 and CEA is useful in increasing early diagnosis rate of breast cancinoma.It could provide more accurate auxiliary diagnosis basis in breast cancer diagnosis,condition monitoring and prognosis evaluation.